Find Oritavancin manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

Annual Reports

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 171099-57-3, Ly333328, Oritavancin [inn], Ly-333328, Chlorobiphenyl-chloroeremomycin, Pug62frz2e
Molecular Formula
C86H97Cl3N10O26
Molecular Weight
1793.1  g/mol
InChI Key
VHFGEBVPHAGQPI-LXKZPTCJSA-N
FDA UNII
PUG62FRZ2E

Oritavancin
Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of single-dose administration and has been proven as non-inferior to a full course of [vancomycin] therapy. On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg. Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and skin structure infections.
Oritavancin is a Lipoglycopeptide Antibacterial. The mechanism of action of oritavancin is as a Cytochrome P450 2C19 Inhibitor, and Cytochrome P450 2C9 Inhibitor, and Cytochrome P450 3A4 Inducer, and Cytochrome P450 2D6 Inducer.
1 2D Structure

Oritavancin

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(1S,2R,18R,19R,22S,25R,28R,40S)-2-[(2R,4S,5R,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5R,6S)-4-[[4-(4-chlorophenyl)phenyl]methylamino]-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-18,32,35,37-tetrahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid
2.1.2 InChI
InChI=1S/C86H97Cl3N10O26/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66-,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-/m0/s1
2.1.3 InChI Key
VHFGEBVPHAGQPI-LXKZPTCJSA-N
2.1.4 Canonical SMILES
CC1C(C(CC(O1)OC2C3C(=O)NC(C4=C(C(=CC(=C4)O)O)C5=C(C=CC(=C5)C(C(=O)N3)NC(=O)C6C7=CC(=C(C(=C7)OC8=C(C=C2C=C8)Cl)OC9C(C(C(C(O9)CO)O)O)OC1CC(C(C(O1)C)O)(C)NCC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)OC1=C(C=C(C=C1)C(C(C(=O)NC(C(=O)N6)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)O)C(=O)O)(C)N)O
2.1.5 Isomeric SMILES
C[C@H]1[C@@H]([C@@](C[C@@H](O1)O[C@H]2[C@H]3C(=O)N[C@@H](C4=C(C(=CC(=C4)O)O)C5=C(C=CC(=C5)[C@H](C(=O)N3)NC(=O)[C@H]6C7=CC(=C(C(=C7)OC8=C(C=C2C=C8)Cl)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O[C@H]1C[C@]([C@H]([C@@H](O1)C)O)(C)NCC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)OC1=C(C=C(C=C1)[C@H]([C@H](C(=O)N[C@H](C(=O)N6)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)O)C(=O)O)(C)N)O
2.2 Other Identifiers
2.2.1 UNII
PUG62FRZ2E
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (4''r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabinohexopyranosyl)-n3''-(p-(p-chlorophenyl)benzyl)vancomycin

2. Ly 333328

3. Ly-333328

4. Ly333328

5. Orbactiv

2.3.2 Depositor-Supplied Synonyms

1. 171099-57-3

2. Ly333328

3. Oritavancin [inn]

4. Ly-333328

5. Chlorobiphenyl-chloroeremomycin

6. Pug62frz2e

7. Chebi:82699

8. Kimyrsa

9. (4''r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabinohexopyranosyl)-n3''-(p-(p-chlorophenyl)benzyl)vancomycin

10. Unii-pug62frz2e

11. Chembl1688530

12. Orita-vancin

13. Ly 333328

14. C12034

15. Oritavancin [mi]

16. Oritavancin [vandf]

17. Oritavancin [mart.]

18. Oritavancin [who-dd]

19. Oritavancin; Ly-333328

20. Schembl9947049

21. Gtpl10877

22. Dtxsid20897570

23. Bdbm513037

24. Ex-a2372

25. Db04911

26. Ncgc00485478-01

27. Ncgc00485478-02

28. Q7102878

29. (4''r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-.alpha.-l-arabino-hexopyranosyl)-n(sup 3)''-(p-(p-chlorophenyl)benzyl)vancomycin

30. (4''r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabino-hexopyranosyl)-n(3'')-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)vancomycin

31. (4'r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabino-hexopyranosyl)-n(sup 3)' -(p-(p-chlorophenyl)benzyl)vancomycin

32. Vancomycin, 22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-.alpha.-l-arabino-hexopyranosyl)-n3''-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)-, (4''r)-

2.4 Create Date
2007-07-04
3 Chemical and Physical Properties
Molecular Weight 1793.1 g/mol
Molecular Formula C86H97Cl3N10O26
XLogP31.5
Hydrogen Bond Donor Count20
Hydrogen Bond Acceptor Count29
Rotatable Bond Count19
Exact Mass1790.564106 g/mol
Monoisotopic Mass1790.564106 g/mol
Topological Polar Surface Area561 Ų
Heavy Atom Count125
Formal Charge0
Complexity3700
Isotope Atom Count0
Defined Atom Stereocenter Count22
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Oritavancin is indicated for the treatment of adult patients with acute bacterial skin and skin structure (including subcutaneous) infection. It is used for confirmed/suspected infections with designated and susceptible gram-positive organisms. There are two preparations of oritavancin; the 400 mg dose that is administered over 3 hours, and the 1200 mg dose administered over 1 hour. Both are indicated for susceptible gram-positive skin and skin structure infections in adults. As antimicrobial susceptibility patterns are geographically distinct, local antibiograms should be consulted to ensure adequate coverage of relevant pathogens prior to use.


FDA Label


Tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults (see sections 4. 4 and 5. 1).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Oritavancin interferes with bacterial cell wall synthesis and integrity, treating susceptible skin and subcutaneous tissue infections with gram-positive bacteria. This drug is known to artifically increase INR and aPTT, interfering with coagulation testing. Cases of infusion reactions have also been reported.


5.2 MeSH Pharmacological Classification

Anti-Bacterial Agents

Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
ORITAVANCIN
5.3.2 FDA UNII
PUG62FRZ2E
5.3.3 Pharmacological Classes
Cytochrome P450 2C9 Inhibitors [MoA]; Cytochrome P450 2D6 Inducers [MoA]; Cytochrome P450 3A4 Inducers [MoA]; Lipoglycopeptide Antibacterial [EPC]; Lipoglycopeptides [CS]; Cytochrome P450 2C19 Inhibitors [MoA]
5.4 ATC Code

J01XA05


J - Antiinfectives for systemic use

J01 - Antibacterials for systemic use

J01X - Other antibacterials

J01XA - Glycopeptide antibacterials

J01XA05 - Oritavancin


5.5 Absorption, Distribution and Excretion

Absorption

Pharmacokinetic analysis of oritavancin revealed a Cmax of 138 and g/mL and an AUC0- of 2800 gh/mL. The AUC0-t in a study of healthy volunteers after an 800 mg dose 1,1111 gh/mL. was also be Another pharmacokinetic study reported a Cmax of 4.7-7.6 micrograms/mL, generally achieved within 24 hours of administration.


Route of Elimination

Oritavancin is excreted as unchanged drug in both the urine and feces. Less than 5% has been recovered in the urine, and 1% has been recovered in the feces.


Volume of Distribution

The volume of distribution of oritavancin is estimated at 87.6 L, suggesting extensive tissue distribution.


Clearance

The clearance of oritavancin is approximately 0.445 L/h. One study revealed a renal clearance of 0.457 mL/min.


5.6 Metabolism/Metabolites

In vitro studies on human hepatocytes suggest that oritavancin is not metabolized, and is excreted unchanged.


5.7 Biological Half-Life

The average terminal half-life of oritavancin is about 245 hours. A pharmacokinetic study revealed a terminal half-life ranging from 135.8-273.8 hours.


5.8 Mechanism of Action

The cell wall is vital for the survival and replication of bacteria, making it a primary target for antibiotic therapy. Oritavancin works against susceptible gram-positive organisms via three separate mechanisms. Firstly, it binds to the stem peptide of peptidoglycan precursors, inhibiting transglycosylation (polymerization). This process normally occurs during cell wall synthesis. Secondly, oritavancin inhibits crosslinking during bacterial cell wall biosynthesis via binding to cell wall pentaglycyl peptide bridging segments. Finally, this drug also acts by disrupting the bacterial cell membrane, interfering with its integrity, which eventually leads to cell death by various mechanisms.


API Reference Price

read-more
read-more
[{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1643308200,"product":"ORITAVANCIN DIPHOSPHATE(FOR R&D PURPOSE)","address":"Plot. No: 24, Second Floor Road No: 5, ALEAP I.E, Pragathi Nag","city":"HYDERABAD","supplier":"GYMA LABORATORIES OF AMERICA, INC.","supplierCountry":"UNITED STATES","foreign_port":"#N\/A","customer":"INNOVATIVE PHARMA SOLUTIONS ","customerCountry":"INDIA","quantity":"0.05","actualQuantity":"50","unit":"GMS","unitRateFc":"0.1","totalValueFC":"5.1","currency":"USD","unitRateINR":"7.5","date":"28-Jan-2022","totalValueINR":"376.5","totalValueInUsd":"5.1","indian_port":"HYDERABAD AIR","hs_no":"29419090","bill_no":"7263495","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"#N\/A","supplierAddress":"","customerAddress":"Plot. No: 24, Second Floor Road No: 5, ALEAP I.E, Pragathi Nag"}]
28-Jan-2022
28-Jan-2022
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Oritavancin Manufacturers

A Oritavancin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Oritavancin, including repackagers and relabelers. The FDA regulates Oritavancin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Oritavancin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Oritavancin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Oritavancin Suppliers

A Oritavancin supplier is an individual or a company that provides Oritavancin active pharmaceutical ingredient (API) or Oritavancin finished formulations upon request. The Oritavancin suppliers may include Oritavancin API manufacturers, exporters, distributors and traders.

click here to find a list of Oritavancin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Oritavancin NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Oritavancin as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Oritavancin API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Oritavancin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Oritavancin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Oritavancin NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Oritavancin suppliers with NDC on PharmaCompass.

Oritavancin GMP

Oritavancin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Oritavancin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Oritavancin GMP manufacturer or Oritavancin GMP API supplier for your needs.

Oritavancin CoA

A Oritavancin CoA (Certificate of Analysis) is a formal document that attests to Oritavancin's compliance with Oritavancin specifications and serves as a tool for batch-level quality control.

Oritavancin CoA mostly includes findings from lab analyses of a specific batch. For each Oritavancin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Oritavancin may be tested according to a variety of international standards, such as European Pharmacopoeia (Oritavancin EP), Oritavancin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Oritavancin USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty